VJHemOnc Podcast Key updates on CAR-T therapy for multiple myeloma
Aug 2, 2021
Nina Shah and other experts discuss the use of CAR-T therapy in multiple myeloma, highlighting the impressive results of the CRB-401 study and the significance of deep responses. They also explore the improvements in quality of life with IDESL treatment, challenges related to determining treatment lines, and the approval of the first cell-based gene therapy. The podcast covers the safety, efficacy, and ongoing studies of Sulta Cell and the use of T-cell engaging antibodies for multiple myeloma, including factors to consider when selecting therapy.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Analysis of CAR-T therapy results in multiple myeloma and comparison to real-world data
01:56 • 4min
Improvements in Quality of Life and Treatment Challenges for Multiple Myeloma Patients
05:48 • 3min
Sulta Cell: Safety, Efficacy, and Ongoing Studies
08:42 • 15min
T-cell Engaging Antibodies for Multiple Myeloma
23:17 • 15min